CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 281 enrolled
Drug / intervention
biopsyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01655017
NCT01655017N/ACompleted
CompareCT.gov

Fibrosis a New Pathological Actor in Adipose Tissue

Assistance Publique - Hôpitaux de Paris·interventional·Posted Aug 1, 2012·Updated Nov 13, 2020

In Brief

A clinical study evaluating biopsy for Obesity and 3 related conditions. Completed, enrolled 281 participants across 2 sites.

Detailed Summary

Adipose tissue (AT) has specific alterations in obesity in particular increased fibrosis amount compared to lean subjects. Fibrosis amount measured by immunohistochemistry on adipose biopsies appears to to predict weight loss response after a bariatric surgery. Non invasive tools to measure fibrosis needs to be validated. The investigators primary aim is to validate a new device able to measure adipose tissue stiffness. Thus the investigators plan to compare the stiffness results obtained with the device to the quantification of fibrosis using immuno-chemistry in massively obese patient's candidates to a bariatric surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Metabolic Diseases, Fibrosis, Body Weight
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 1, 2012
Enrollment StartFeb 8, 2012
Primary CompletionApr 6, 2018
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 13.9 years ago

Interventions

biopsyprocedure

adipose tissue biopsy (to evaluate inflammation and fibrosis)